ArticleJournal of orthopaedic translation2026
TTC26 scaffolds MINDY3-mediated RACK1 deubiquitination to drive osteoclastogenesis and pathological bone resorption.
Article in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From local tissue repair to systemic precision orthopaedics: recent advances in musculoskeletal regeneration and translational medicine.Journal of orthopaedic translation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoclast overactivation is a central driver of bone metabolic disorders such as osteoporosis, and novel drug targets for these diseases continue to be actively explored. Scaffold proteins, which enhance the specificity of deubiquitinase (DUB)-substrate interactions, have emerged as promising therapeutic targets for the sustained management of chronic diseases. Intraflagellar transport (IFT) proteins, recognized for their scaffolding roles in cellular signaling, are increasingly implicated in bone remodeling. However, their therapeutic potential for bone metabolic disorders remains to be fully elucidated. Methods: We systematically investigated the function of the core IFT protein, tetratricopeptide repeat protein 26 (TTC26), in osteoclastogenesis through clinical correlation analysis and mouse models ( Results: We identified TTC26 as a previously unrecognized regulator of osteoclast differentiation. Acting as a scaffold protein, TTC26 recruits the DUB ubiquitin carboxyl-terminal hydrolase-3 (MINDY3) to promote K48-linked deubiquitination of receptor for activated kinase C-1 (RACK1), thereby stabilizing RACK1 and activating nuclear factor of activated T cells 1 (NFATc1), the master transcription factor of osteoclastogenesis. Furthermore, structural analysis reveals that six critical TTC26 residues (N533, T534, E537, R541, K545, and K548) are essential for this scaffold activity. Notably, osteoclast-targeted inhibition of Conclusion: Our findings uncover a novel role for TTC26 in bone homeostasis and elucidate its molecular mechanism in driving osteoclastogenesis by scaffolding MINDY3-mediated deubiquitination of RACK1. Translational potential: This study holds clear clinical translational prospects: 1) TTC26 may serve as a novel biomarker for osteoporosis diagnosis; 2) Its functional residues provide precise targets for developing small-molecule inhibitors; 3) The scaffold protein regulatory paradigm offers a new model that can be referenced for treating other bone metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.